CorMedix Inc.
CRMDCorMedix Inc. in brief
CorMedix Inc. is a listed company in the Biotechnology industry, based in Parsippany, New Jersey, USA. It was founded in 2006. Its market value was $652 M on 29 October 2026, which makes it the 11,419th largest listed company in the world and the 2,363rd largest in the USA on this site. In the year to December 2025 it had sales of $312 M and a net profit of $163 M, about 52 cents of profit for every dollar of sales. It employs about 191 people and Joseph Todisco is its chief executive. Its largest product and service lines by sales in 2025 were DefenCath (83%), Melinta Portfolio (15%) and Contract revenue (2%). Its shares trade under the symbol CRMD (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. Our primary focus has been commercializing DefenCath® (taurolidine and heparin), in the U.S., which we launched in 2024 in the hemodialysis setting. The name DefenCath is the U.S. proprietary name approved by the U.S. Food and Drug Administration.
On August 29, 2025, the Company acquired Melinta Therapeutics, LLC, a Delaware limited liability company, which expanded the Company’s team, commercial platform and increased the commercial portfolio with six marketed, hospital- and clinic-focused infectious disease products, comprised of REZZAYO® (rezafungin for injection), MINOCIN® (minocycline) for Injection, VABOMERE® (meropenem and vaborbactam), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin), and BAXDELA® (delafloxacin), as well as an additional well-established cardiovascular product, TOPROL-XL® (metoprolol succinate). The Melinta Portfolio supports a multi-channel strategy of delivering anti-infectives for serious gram-positive, gram-negative and fungal infections within hospitals and the hospital ecosystem, including emergency departments, outpatient clinics and home infusion care, and provides synergy opportunities to drive growth for DefenCath.
From the company's annual report filed with the US SEC: read the report
CorMedix Inc. timeline
- 2006
- 🏁· approximateFounded
- 2007
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2025
- 💰Record revenue of $312 millionFY2025, the highest of the 7 years on record.
Events of CorMedix Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,320 (Jan 2020) · #3,116 (Jan 2021) · #3,909 (Jan 2022) · #3,835 (Dec 2022) · #3,461 (Jul 2023) · #3,265 (Jan 2024) · #1,222 (Mar 2026) · #2,435 (Aug 2026) · #2,395 (Sep 2026) · #2,365 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- 10.2×
- Price / sales (TTM)
- 1.6×
- Price / book
- 1.6×
- Free cash flow yield
- 26.5%
- Net margin (TTM)
- 15.5%
- Operating margin
- 48.2%
- Return on equity
- 15.8%
- Liabilities / assets
- 50.9%
- Revenue growth
- +617.1%
- R&D / revenue
- 6.2%
- Revenue per employee
- $1.6 M
- Profit per employee
- $854 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $312M | +617.1% | $150M | $163M | 52.3% |
| Dec 2024 | $43M | — | $-22M | $-18M | -41.2% |
| Dec 2023 | — | — | $-49M | $-46M | — |
| Dec 2022 | $0M | -63.2% | $-31M | $-30M | -42428.6% |
| Dec 2021 | $0M | -20.8% | $-29M | $-28M | -14847.4% |
| Dec 2020 | $0M | -14.3% | $-27M | $-22M | -9179.2% |
| Dec 2019 | $0M | -34.9% | $-21M | $-16M | -5867.9% |
| Dec 2018 | $0M | — | $-27M | $-27M | -6239.5% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $175M | $2M | $173M | $2.04 | — |
| Dec 2024 | $-51M | $0M | $-51M | $-0.30 | — |
| Dec 2023 | $-38M | $0M | $-39M | $-0.91 | — |
| Dec 2022 | $-24M | $0M | $-25M | $-0.74 | — |
| Dec 2021 | $-21M | $1M | $-23M | $-0.75 | — |
| Dec 2020 | $-22M | $0M | $-22M | $-0.77 | — |
| Dec 2019 | $-15M | $0M | $-15M | $-1.80 | — |
| Dec 2018 | $-24M | $0M | $-24M | $-1.51 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $55M (-47.7% on a year earlier), net income $-15M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 10, 20268-KCurrent reportRegulation FD disclosure
- Nov 9, 20268-KCurrent reportMaterial agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure
- Nov 2, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Oct 19, 20268-KCurrent reportRegulation FD disclosure
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Aug 7, 20268-KCurrent reportOther events
- Jul 2, 20268-KCurrent reportOther events
- Jul 1, 20268-KCurrent reportAuditor change
- Jun 24, 20268-KCurrent reportShareholder vote
Official filings of CorMedix Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $312 M
- Operating income
- $150 M
- Net income
- $163 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $826 M
- Total liabilities
- $421 M
- Total equity
- $405 M
As of December-2025
Top 100 institutional investors in CorMedix Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 6,453,154 | +129,043 (+2.04%) | 8.11% | $50 M | Nov 13, 2026 |
| 2 | Deep Track Capital, LP | 6,274,076 | 0 (0.00%) | 7.89% | $48 M | Nov 16, 2026 |
| 3 | Vanguard Capital Management LLC | 3,051,570 | -83,505 (-2.66%) | 3.84% | $23 M | Nov 13, 2026 |
| 4 | American Century Companies Inc | 2,722,920 | +2,377,579 (+688.47%) | 3.42% | $21 M | Nov 12, 2026 |
| 5 | State Street Corp | 2,637,468 | +320,623 (+13.84%) | 3.32% | $20 M | Nov 12, 2026 |
| 6 | UBS Group AG | 2,253,235 | +375,295 (+19.98%) | 2.83% | $17 M | Nov 10, 2026 |
| 7 | Geode Capital Management, LLC | 1,909,979 | -37,035 (-1.90%) | 2.40% | $15 M | Nov 6, 2026 |
| 8 | Royce & Associates LP | 1,659,947 | -516,415 (-23.73%) | 2.09% | $13 M | Nov 9, 2026 |
| 9 | Oberweis Asset Management Inc/ | 1,322,570 | -1,345 (-0.10%) | 1.66% | $10 M | Nov 16, 2026 |
| 10 | Goldman Sachs Group Inc | 1,249,382 | +782,989 (+167.88%) | 1.57% | $10 M | Nov 16, 2026 |
| 11 | Marshall Wace, LLP | 1,195,422 | +415,887 (+53.35%) | 1.50% | $9 M | Nov 13, 2026 |
| 12 | Alyeska Investment Group, L.P. | 850,000 | 0 (0.00%) | 1.07% | $7 M | Nov 16, 2026 |
| 13 | Armistice Capital, LLC | 836,000 | +336,000 (+67.20%) | 1.05% | $6 M | Nov 16, 2026 |
| 14 | Vanguard Portfolio Management LLC | 730,455 | +21,851 (+3.08%) | 0.92% | $6 M | Nov 13, 2026 |
| 15 | Trexquant Investment LP | 719,148 | +95,351 (+15.29%) | 0.90% | $6 M | Nov 16, 2026 |
| 16 | Northern Trust Corp | 718,296 | -38,134 (-5.04%) | 0.90% | $6 M | Nov 16, 2026 |
| 17 | Morgan Stanley | 641,157 | +217,816 (+51.45%) | 0.81% | $5 M | Nov 13, 2026 |
| 18 | Charles Schwab Investment Management Inc | 616,302 | -1,870 (-0.30%) | 0.77% | $5 M | Nov 16, 2026 |
| 19 | HRT Financial LP | 610,228 | -15,330 (-2.45%) | 0.77% | $5 M | Nov 13, 2026 |
| 20 | Hennion & Walsh Asset Management, Inc. | 536,909 | +98,280 (+22.41%) | 0.68% | $4 M | Oct 13, 2026 |
| 21 | Bridgeway Capital Management, LLC | 459,223 | +25,091 (+5.78%) | 0.58% | $4 M | Nov 16, 2026 |
| 22 | Vanguard Fiduciary Trust Co | 448,511 | -35,811 (-7.39%) | 0.56% | $3 M | Nov 13, 2026 |
| 23 | Kennedy Capital Management LLC | 407,703 | -11,581 (-2.76%) | 0.51% | $3 M | Nov 13, 2026 |
| 24 | Bank of New York Mellon Corp | 372,274 | -23,633 (-5.97%) | 0.47% | $3 M | Nov 5, 2026 |
| 25 | Raymond James Financial Inc | 359,047 | -87,095 (-19.52%) | 0.45% | $3 M | Nov 12, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | First Trust Advisors LP | 342,855 | +294,509 (+609.17%) | 0.43% | $3 M | Nov 12, 2026 |
| 27 | D. E. Shaw & Co., Inc. | 330,468 | +158,661 (+92.35%) | 0.42% | $3 M | Nov 16, 2026 |
| 28 | Ameriprise Financial Inc | 274,503 | -1,784 (-0.65%) | 0.35% | $2 M | Nov 16, 2026 |
| 29 | Empowered Funds, LLC | 268,323 | +25,091 (+10.32%) | 0.34% | $2 M | Nov 13, 2026 |
| 30 | Wellington Management Group LLP | 263,406 | +47,611 (+22.06%) | 0.33% | $2 M | Nov 16, 2026 |
| 31 | Jpmorgan Chase & Co | 262,755 | +195,340 (+289.76%) | 0.33% | $2 M | Nov 12, 2026 |
| 32 | Steward Partners Investment Advisory, LLC | 234,292 | +1,677 (+0.72%) | 0.29% | $2 M | Nov 13, 2026 |
| 33 | Principal Financial Group Inc | 217,939 | +26,998 (+14.14%) | 0.27% | $2 M | Nov 2, 2026 |
| 34 | Commonwealth Equity Services, LLC | 212,135 | -2,725 (-1.27%) | 0.27% | $2 M | Nov 2, 2026 |
| 35 | Quantinno Capital Management LP | 197,568 | +57,530 (+41.08%) | 0.25% | $2 M | Nov 13, 2026 |
| 36 | Nuveen, LLC | 183,428 | -1,846 (-1.00%) | 0.23% | $1 M | Nov 10, 2026 |
| 37 | Susquehanna International Group, LLP | 174,658 | -144,310 (-45.24%) | 0.22% | $1 M | Nov 16, 2026 |
| 38 | Two Sigma Investments, LP | 159,965 | +119,106 (+291.50%) | 0.20% | $1 M | Nov 16, 2026 |
| 39 | Bank Of America Corp /de/ | 158,462 | +7,806 (+5.18%) | 0.20% | $1 M | Nov 16, 2026 |
| 40 | Private Advisor Group, LLC | 154,755 | -260,651 (-62.75%) | 0.19% | $1 M | Nov 10, 2026 |
| 41 | Swiss National Bank | 146,800 | +8,000 (+5.76%) | 0.18% | $1 M | Nov 12, 2026 |
| 42 | Wingate Wealth Advisors, Inc. | 128,002 | -500 (-0.39%) | 0.16% | $1 M | Oct 26, 2026 |
| 43 | Profund Advisors LLC | 127,465 | +104,629 (+458.18%) | 0.16% | $1 M | Oct 29, 2026 |
| 44 | Palisades Investment Partners, LLC | 122,188 | -304,355 (-71.35%) | 0.15% | $1 M | Nov 3, 2026 |
| 45 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 107,049 | -6,691 (-5.88%) | 0.13% | $1 M | Nov 16, 2026 |
| 46 | Credit Agricole S A | 104,000 | 0 (0.00%) | 0.13% | $1 M | Nov 13, 2026 |
| 47 | Franklin Templeton Inc | 101,175 | +77,739 (+331.71%) | 0.13% | $1 M | Nov 12, 2026 |
| 48 | West Michigan Advisors, LLC | 97,500 | +31,500 (+47.73%) | 0.12% | $1 M | Nov 9, 2026 |
| 49 | LPL Financial LLC | 94,191 | -43,975 (-31.83%) | 0.12% | $1 M | Nov 6, 2026 |
| 50 | Rhumbline Advisers | 90,759 | -3,179 (-3.38%) | 0.11% | $1 M | Nov 10, 2026 |
| 51 | Corient Private Wealth LP | 90,472 | -5,468 (-5.70%) | 0.11% | $1 M | Nov 16, 2026 |
| 52 | AQR Capital Management LLC | 86,517 | -64,918 (-42.87%) | 0.11% | $1 M | Nov 16, 2026 |
| 53 | Magnetar Financial LLC | 85,342 | +48,825 (+133.70%) | 0.11% | $1 M | Nov 13, 2026 |
| 54 | Easterly Investment Partners LLC | 83,688 | +318 (+0.38%) | 0.11% | $1 M | Nov 12, 2026 |
| 55 | California State Teachers Retirement System | 75,639 | 0 (0.00%) | 0.10% | $1 M | Nov 13, 2026 |
| 56 | Barclays PLC | 74,738 | +30,979 (+70.79%) | 0.09% | $1 M | Nov 6, 2026 |
| 57 | Alps Advisors Inc | 73,550 | New | 0.09% | $1 M | Nov 3, 2026 |
| 58 | Deutsche Bank AG\ | 72,301 | -5,082 (-6.57%) | 0.09% | $1 M | Nov 6, 2026 |
| 59 | Jump Financial, LLC | 65,910 | -114,117 (-63.39%) | 0.08% | $1 M | Nov 13, 2026 |
| 60 | Birchview Capital, LP | 65,874 | New | 0.08% | $1 M | Nov 13, 2026 |
| 61 | Price T Rowe Associates Inc /MD/ | 62,054 | 0 (0.00%) | 0.08% | $0 M | Nov 16, 2026 |
| 62 | Alliancebernstein L.P. | 61,780 | 0 (0.00%) | 0.08% | $0 M | Nov 16, 2026 |
| 63 | Concurrent Investment Advisors, LLC | 61,483 | +18,083 (+41.67%) | 0.08% | $0 M | Oct 16, 2026 |
| 64 | Man Group plc | 60,851 | New | 0.08% | $0 M | Nov 16, 2026 |
| 65 | Citigroup Inc | 58,679 | -7,549 (-11.40%) | 0.07% | $0 M | Nov 4, 2026 |
| 66 | Legal & General Group Plc | 58,595 | 0 (0.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 67 | State of Alaska, Department of Revenue | 57,664 | -4,694 (-7.53%) | 0.07% | $0 M | Oct 15, 2026 |
| 68 | Engineers Gate Manager LP | 54,678 | -11,878 (-17.85%) | 0.07% | $0 M | Nov 16, 2026 |
| 69 | Renaissance Technologies LLC | 54,577 | New | 0.07% | $0 M | Nov 12, 2026 |
| 70 | Pekin Hardy Strauss, Inc. | 54,000 | 0 (0.00%) | 0.07% | $0 M | Nov 2, 2026 |
| 71 | Canada Pension Plan Investment Board | 49,500 | +14,000 (+39.44%) | 0.06% | $0 M | Nov 16, 2026 |
| 72 | CIBC Bancorp USA Inc. | 49,373 | +3,256 (+7.06%) | 0.06% | $0 M | Nov 13, 2026 |
| 73 | VANGUARD ASSET MANAGEMENT, Ltd | 49,040 | 0 (0.00%) | 0.06% | $0 M | Nov 13, 2026 |
| 74 | ExodusPoint Capital Management, LP | 48,661 | -87,143 (-64.17%) | 0.06% | $0 M | Nov 16, 2026 |
| 75 | Prudential Financial Inc | 46,344 | +34,074 (+277.70%) | 0.06% | $0 M | Nov 16, 2026 |
| 76 | Lido Advisors, LLC | 44,707 | 0 (0.00%) | 0.06% | $0 M | Nov 4, 2026 |
| 77 | Entropy Technologies, LP | 43,155 | New | 0.05% | $0 M | Nov 13, 2026 |
| 78 | Invesco Ltd. | 41,452 | -3,908 (-8.62%) | 0.05% | $0 M | Nov 12, 2026 |
| 79 | Citadel Advisors LLC | 38,292 | -18,322 (-32.36%) | 0.05% | $0 M | Nov 16, 2026 |
| 80 | SEI Investments Co | 35,905 | 0 (0.00%) | 0.05% | $0 M | Nov 10, 2026 |
| 81 | Bleakley Financial Group, LLC | 35,674 | New | 0.04% | $0 M | Nov 13, 2026 |
| 82 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 35,609 | +1,265 (+3.68%) | 0.04% | $0 M | Nov 16, 2026 |
| 83 | MetLife Investment Management, LLC | 35,368 | -6,145 (-14.80%) | 0.04% | $0 M | Nov 16, 2026 |
| 84 | Creative Planning | 34,126 | -997 (-2.84%) | 0.04% | $0 M | Nov 2, 2026 |
| 85 | Schonfeld Strategic Advisors LLC | 33,959 | +3,806 (+12.62%) | 0.04% | $0 M | Nov 16, 2026 |
| 86 | Wealth Enhancement Advisory Services, LLC | 33,011 | -3,458 (-9.48%) | 0.04% | $0 M | Oct 13, 2026 |
| 87 | Russell Investments Group, Ltd. | 32,646 | -7,146 (-17.96%) | 0.04% | $0 M | Nov 6, 2026 |
| 88 | Sigma Planning Corp | 32,142 | +2,531 (+8.55%) | 0.04% | $0 M | Oct 23, 2026 |
| 89 | Gryphon Financial Partners LLC | 31,001 | +942 (+3.13%) | 0.04% | $0 M | Nov 4, 2026 |
| 90 | State Of Wisconsin Investment Board | 30,749 | +1,589 (+5.45%) | 0.04% | $0 M | Nov 16, 2026 |
| 91 | VIRGINIA RETIREMENT SYSTEMS ET Al | 30,700 | -800 (-2.54%) | 0.04% | $0 M | Oct 28, 2026 |
| 92 | HighTower Advisors, LLC | 30,425 | -2,230 (-6.83%) | 0.04% | $0 M | Nov 10, 2026 |
| 93 | Beacon Pointe Advisors, LLC | 29,000 | +5,000 (+20.83%) | 0.04% | $0 M | Nov 16, 2026 |
| 94 | Quantbot Technologies LP | 28,358 | +17,561 (+162.65%) | 0.04% | $0 M | Nov 12, 2026 |
| 95 | Truist Financial Corp | 27,626 | +5,480 (+24.74%) | 0.03% | $0 M | Oct 30, 2026 |
| 96 | Janus Henderson Group Ltd. | 26,900 | — | 0.03% | $0 M | Nov 16, 2026 |
| 97 | Royal Capital Wealth Management, LLC | 24,500 | -4,000 (-14.04%) | 0.03% | $0 M | Nov 16, 2026 |
| 98 | Vanguard Global Advisers, LLC | 24,245 | -3,473 (-12.53%) | 0.03% | $0 M | Nov 13, 2026 |
| 99 | Royal Bank Of Canada | 23,656 | +804 (+3.52%) | 0.03% | $0 M | Nov 16, 2026 |
| 100 | Wells Fargo & Company/mn | 23,438 | -45,558 (-66.03%) | 0.03% | $0 M | Nov 16, 2026 |
Mutual funds holding CorMedix Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 2.23 M | $17 M | 2.8% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.94 M | $15 M | 2.4% | 0.02% | +4.8% | Jun 30, 2026 |
| 🇺🇸 Oberweis Micro-Cap FundOberweis Asset Management, Inc. | 1.28 M | $10 M | 1.6% | 0.62% | +9.9% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 824,083 | $6 M | 1.0% | <0.01% | −0.6% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 816,503 | $6 M | 1.0% | 0.02% | +11% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 683,402 | $5 M | 0.86% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Pacer US Small Cap Cash Cows 100 ETFPacer Advisors, Inc. | 626,124 | $5 M | 0.79% | 0.13% | +8.9% | Jul 31, 2026 |
| 🇺🇸 Royce Small-Cap Opportunity FundRoyce & Associates, LP | 566,897 | $4 M | 0.71% | 0.32% | +36% | Jun 30, 2026 |
| 🇺🇸 Royce Small-Cap FundRoyce & Associates, LP | 562,746 | $4 M | 0.71% | 0.21% | −6.8% | Jun 30, 2026 |
| 🇺🇸 State Street SPDR S&P Pharmaceuticals ETFSSGA Funds Management, Inc. | 549,805 | $4 M | 0.69% | 1.0% | −0.8% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 381,249 | $3 M | 0.48% | <0.01% | −1.1% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 381,233 | $3 M | 0.48% | 0.02% | +3.6% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 347,750 | $3 M | 0.44% | 0.01% | −1.5% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 250,705 | $2 M | 0.32% | 0.13% | +34% | Jun 30, 2026 |
| 🇺🇸 Royce Capital Fund - Small-Cap PortfolioRoyce & Associates, LP | 245,212 | $2 M | 0.31% | 1.0% | −14% | Jun 30, 2026 |
| 🇺🇸 EA Bridgeway Omni Small-Cap Value ETFEmpowered Funds, LLC d/b/a EA Advisers | 243,232 | $2 M | 0.31% | 0.08% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 220,892 | $2 M | 0.28% | <0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 VictoryShares Small Cap Free Cash Flow ETFVictory Capital Management Inc. | 202,848 | $2 M | 0.26% | 0.26% | −59% | Jun 30, 2026 |
| 🇺🇸 iShares U.S. Pharmaceuticals ETFBlackRock Fund Advisors | 190,159 | $1 M | 0.24% | 0.13% | −7.1% | Jun 30, 2026 |
| 🇺🇸 Omni Small-Cap Value FundBridgeway Capital Management, LLC | 190,000 | $1 M | 0.24% | 0.11% | new | Jun 30, 2026 |
| 🇺🇸 Principal U.S. Small-Cap ETFPrincipal Global Investors, LLC | 187,228 | $1 M | 0.24% | 0.06% | +7.7% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 181,355 | $1 M | 0.23% | 0.02% | +10% | Jul 31, 2026 |
| 🇺🇸 Royce Small-Cap Value FundRoyce & Associates, LP | 146,768 | $1 M | 0.18% | 1.0% | — | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 136,166 | $1 M | 0.17% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 139,411 | $1 M | 0.18% | 0.02% | +16% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 111,717 | $1 M | 0.14% | <0.01% | +4.4% | May 31, 2026 |
| 🇺🇸 WisdomTree U.S. SmallCap FundWisdomTree Asset Management, Inc. | 119,246 | $1 M | 0.15% | 0.13% | −2.3% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 104,378 | $1 M | 0.13% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P. | 96,006 | $1 M | 0.12% | 0.08% | +69% | May 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 100,286 | $1 M | 0.13% | <0.01% | +2.5% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 99,068 | $1 M | 0.12% | 0.02% | +11% | Jul 31, 2026 |
| 🇺🇸 Easterly Snow Long/Short Opportunity FundEasterly Investment Partners LLC | 76,000 | $1 M | 0.10% | 0.58% | new | May 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 80,596 | $1 M | 0.10% | 0.02% | +0.3% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 70,036 | $1 M | 0.09% | 0.04% | +2.9% | May 31, 2026 |
| 🇺🇸 Vanguard U.S. Multifactor ETFThe Vanguard Group, Inc. | 69,653 | $1 M | 0.09% | 0.09% | −30% | May 31, 2026 |
| 🇺🇸 Small Cap Value FundNorthern Trust Investments, Inc. | 71,301 | $1 M | 0.09% | 0.08% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 74,114 | $1 M | 0.09% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 46,045 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 47,500 | $0 M | 0.06% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 48,604 | $0 M | 0.06% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 40,673 | $0 M | 0.05% | <0.01% | +1.2% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 39,264 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 38,378 | $0 M | 0.05% | 0.02% | +18% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 39,401 | $0 M | 0.05% | <0.01% | +4.2% | Jul 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 35,910 | $0 M | 0.05% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 35,613 | $0 M | 0.04% | 0.02% | +11% | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 31,191 | $0 M | 0.04% | 0.02% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 33,128 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC | 31,479 | $0 M | 0.04% | <0.01% | −7.4% | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 26,402 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 26,500 | $0 M | 0.03% | <0.01% | −0.7% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 27,093 | $0 M | 0.03% | <0.01% | +3.2% | Jul 31, 2026 |
| 🇺🇸 Acuitas US Microcap FundAcuitas Investments, LLC | 24,695 | $0 M | 0.03% | 0.16% | — | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 22,538 | $0 M | 0.03% | 0.02% | −8.5% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 22,506 | $0 M | 0.03% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 21,390 | $0 M | 0.03% | 0.02% | +18% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 21,100 | $0 M | 0.03% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 20,440 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Venerable US Small Cap FundVenerable Investment Advisers, LLC | 19,749 | $0 M | 0.02% | 0.10% | +44% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 16,709 | $0 M | 0.02% | 0.06% | +25% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 16,369 | $0 M | 0.02% | 0.02% | +11% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 14,886 | $0 M | 0.02% | 0.02% | +10% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Value PortfolioPacific Life Fund Advisors LLC | 14,879 | $0 M | 0.02% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 14,188 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 11,715 | $0 M | 0.01% | 0.02% | +9.7% | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 12,076 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 11,457 | $0 M | 0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 11,375 | $0 M | 0.01% | 0.02% | +33% | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 11,345 | $0 M | 0.01% | 0.02% | +2.1% | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 10,444 | $0 M | 0.01% | 0.02% | +16% | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 9,000 | $0 M | 0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 9,105 | $0 M | 0.01% | 0.02% | +19% | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 8,888 | $0 M | 0.01% | <0.01% | +9.4% | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 8,301 | $0 M | 0.01% | 0.02% | no change | Jul 31, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 6,881 | $0 M | <0.01% | 0.02% | +16% | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 6,562 | $0 M | <0.01% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 6,371 | $0 M | <0.01% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 6,006 | $0 M | <0.01% | <0.01% | +28% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 5,357 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 5,724 | $0 M | <0.01% | <0.01% | −12% | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 5,497 | $0 M | <0.01% | 0.02% | −7.3% | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 5,030 | $0 M | <0.01% | 0.02% | +7.2% | Jun 30, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 4,992 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares MSCI World Small-Cap ETFBlackRock Fund Advisors | 4,403 | $0 M | <0.01% | <0.01% | −25% | May 31, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 4,924 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 3,494 | $0 M | <0.01% | 0.02% | +8.7% | May 31, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 3,654 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 3,296 | $0 M | <0.01% | <0.01% | −36% | Jun 30, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 2,762 | $0 M | <0.01% | <0.01% | −40% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 2,733 | $0 M | <0.01% | <0.01% | −41% | May 31, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 2,648 | $0 M | <0.01% | <0.01% | −5.0% | May 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 2,595 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 1,791 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 1,897 | $0 M | <0.01% | <0.01% | +11% | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 1,796 | $0 M | <0.01% | <0.01% | +1.8% | Jun 30, 2026 |
| 🇺🇸 TIAA Separate Account VA-1 - Stock Index AccountTeachers Advisors, LLC | 1,679 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street SPDR Portfolio MSCI Global Stock Market ETFSSGA Funds Management, Inc. | 1,664 | $0 M | <0.01% | <0.01% | +14% | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 1,457 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 1,209 | $0 M | <0.01% | <0.01% | +2.0% | Jun 30, 2026 |
| 🇺🇸 Nuveen Life Stock Index FundTeachers Advisors, LLC | 889 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at CorMedix Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Myron KaplanDirector | Buy | +25,000 | $4.880 | $122 K | 256,487 | Form 4 |
| filed | Joseph TodiscoChief Executive Officer, Director | Buy | +80,000 | $4.890 | $391 K | 854,749 | Form 4 |
| filed | Janet DillioneDirector | Option exercise | +48,909 | — | — | 117,835 | Form 4 |
| filed | Kaufman Beth ZelnickChief Legal Officer | Shares withheld for tax | -8,424 | $8.300 | $70 K | 260,684 | Form 4 |
| filed | Elizabeth HurlburtChief Operating Officer | Shares withheld for tax | -8,076 | $8.300 | $67 K | 270,463 | Form 4 |
| filed | Susan BlumChief Financial Officer | Shares withheld for tax | -8,424 | $8.300 | $70 K | 124,315 | Form 4 |
| filed | Joseph TodiscoChief Executive Officer, Director | Grant or award | +77,156 | — | — | 774,749 | Form 4 |
| filed | Kaufman Beth ZelnickChief Legal Officer | Grant or award | +36,006 | — | — | 269,108 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: CorMedix Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q3 2026 | Q3 2026 | $0M |
| Q2 2026 | Q2 2026 | $6.4M |
| Q1 2026 | Q1 2026 | $11.1M |
| Q3 2025 | Q3 2026 | $0M |
| Q2 2025 | Q2 2026 | $0M |
| Q1 2025 | Q1 2026 | $0M |
Fails to deliver
- : 13,428 shares at $8.20
- : 959 shares at $8.00
- : 726 shares at $7.94
- : 36,938 shares at $7.57
- : 55 shares at $7.38
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
CorMedix Inc. scorecard#
Passes 14 of the 17 checks that could be worked out: strongest in valuation (5 of 5), weakest in financial health (2 of 3). Fiscal year 2025; market cap of Oct 29, 2026.
Valuation5 of 5
- ✓P/E below its peers' median10.2×P/E 10.2× against Biotechnology's median of 17.5×.
- ✓Price to book below its peers' median1.6×Price to book 1.6× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median1.6×Price to sales 1.6× against Biotechnology's median of 8.7×.
- ✓Free cash flow yield above 5%26.5%Free cash flow is 26.5% of the market value.
- ✓Earnings yield above the 10-year Treasury yield9.8%Earnings yield 9.8% against the 10-year Treasury's 5.15% on 2026-11-13.
- –The price assumes slower growth than the last three years'No revenue growth over three years on file.
Growth3 of 3
- ✓Revenue grew in the newest year617.1%Revenue up 617.1% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✓Earnings per share grew in the newest year2.04 vs -0.30Diluted EPS 2.04 in fiscal 2025 against -0.30 the year before (report's currency).
- ✓Net income higher than five years earlier$163 M$163 M in fiscal 2025 against -$22 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability4 of 5
- ✓Profitable in the newest year$163 MNet income $163 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median48.2%48.2% against Biotechnology's median of -60.5% (243 companies).
- ✓Return on equity above 15%66.6%66.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier48.2%48.2% in fiscal 2025 against -43742.9% in 2022.
Financial health2 of 3
- ✓Short-term assets cover short-term liabilities2.1×Current ratio 2.11 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone1.89Z-score 1.89 (grey zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year35.6%Diluted shares up 35.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from CorMedix Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | 48.2% | -60.5% | |
| Net margin | 52.3% | -68.9% | |
| Return on equity | 66.6% | -61.0% | |
| Revenue growth | 617.1% | 15.8% | |
| Free cash flow margin | 55.4% | -61.5% |
5of 8on the Piotroski tests of financial strength
- The share count rose 35.6% in the year.
- Goodwill and intangibles ($409 million) exceed shareholders' equity ($405 million).
CorMedix Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 312+617%100% | 43r43—100% | — | 0.1−65.7%100% | 0.2−20.2%100% | 0.2−15.5%100% | 0.3−34.1%100% | 0.4+30.5%100% | 0.3+47.0%100% | 0.2—100% | |
| Cost of revenue | 22+628%7.1% | 3.0r3.2—7.0% | — | 0.0−97.5%5.7% | 0.1−27.3%78.0% | 0.2−45.1%85.6% | 0.4−5.9%132% | 0.4+245%92.3% | 0.1−68.6%34.9% | 0.4r−0.4—164% | |
| Gross profit | 276+585%88.5% | 40r40—92.7% | — | 0.1+46.8%94.3% | 0.0+22.1%22.0% | 0.0—14.4% | −0.1−373%−31.8% | 0.0−84.6%7.7% | 0.2—65.1% | −0.1—−63.6% | |
| Research and development | 19+390%6.2% | 3.9r3.9−70.0%9.1% | 13+23.2%— | 11−18.7%16328% | 13−1.8%6878% | 13+21.0%5592% | 11−41.3%3902% | 19−23.1%4379% | 24+55.6%7435% | 16—7021% | |
| Selling, general and administrative | — | — | 36+79.0%— | 20+22.4%30587% | 16+17.8%8561% | 14+40.7%5801% | 9.9+22.2%3483% | 8.1—1879% | — | — | |
| Selling and marketing | 38+32.4%12.2% | 29r29+58.6%66.1% | 18—— | — | — | — | — | — | — | — | |
| General and administrative | 68+128%21.9% | 30r30+69.4%68.9% | 18—— | — | — | — | — | 8.1−6.7%1879% | 8.7−2.6%2627% | 8.9—3964% | |
| Operating expenses | 126+101%40.3% | 63r63+27.9%144% | 49+59.5%— | 31+4.1%46914% | 29+8.2%15440% | 27+30.3%11393% | 21−22.2%7385% | 27−18.8%6258% | 33+34.6%10062% | 25—10985% | |
| Total costs and expenses | — | — | — | — | 3.0—1579% | — | — | — | — | — | |
| Operating income | 150—48.2% | −22r−22—−51.4% | −49—— | −31—−46820% | −29—−15418% | −27—−11378% | −21—−7416% | −27—−6250% | −33—−9997% | −25—−11049% | |
| Interest and finance income | 3.8+49.1%1.2% | 2.6r2.6−3.8%5.9% | 2.7—— | — | — | 0.1−64.0%48.5% | 0.3+781%114% | 0.0−66.9%8.5% | 0.1−12.7%33.6% | 0.1—56.6% | |
| Interest expense and finance costs | 2.8+7628%0.9% | 0.0r0.0+5.0%0.1% | 0.0+29.3%— | 0.0+66.3%40.5% | 0.0−52.0%8.3% | 0.0−95.8%13.9% | 0.8+41944%278% | 0.0−66.7%0.4% | 0.0+329%1.7% | 0.0—0.6% | |
| Net interest income | — | 1.4—3.2% | — | — | — | — | — | — | — | — | |
| Other non-operating income (expense) | −0.1−104%−0.0% | 3.0r3.0+15.8%7.0% | 2.6+678%— | 0.3—515% | −0.0−196%−12.0% | 0.0—9.9% | −0.5−1506%−172% | 0.0—8.0% | −0.1—−26.1% | — | |
| Income before tax | 150—48.1% | −19r−19—−44.5% | −46—— | −30—−46305% | −29—−15429% | −27—−11369% | −21—−7588% | −27—−6242% | −33—−10023% | −25—−10996% | |
| Income tax | −13—−4.2% | −1.4r−1.4—−3.2% | — | −0.6—−895% | −1.3—−655% | −5.2—−2161% | −5.1—−1787% | — | — | — | |
| Income from continuing operations | 1.7—0.5% | — | — | — | — | — | — | — | — | — | |
| Net income including minority interests | — | — | — | — | −28—−14775% | −22—−9208% | −16—−5801% | — | — | — | |
| Minority interests' share of net income | — | — | — | — | 28+28.2%14769% | 22—9196% | — | — | — | — | |
| Net income attributable to shareholders | 163—52.3% | −18r−18—−41.2% | −46—— | −30—−45410% | −28—−14775% | −22—−9208% | −16—−5801% | −27—−6242% | −33—−10023% | −25—−10996% | |
| Earnings per share, basic | 2.25—— | -0.30—— | -0.91—— | -0.74—— | -0.75—— | -0.77—— | -1.80—— | -1.51r-0.30—— | -0.60—— | -0.65—— | |
| Earnings per share, diluted | 2.04—— | -0.30—— | -0.91—— | -0.74—— | -0.75—— | -0.77—— | -1.80—— | -1.51r-0.30—— | -0.60—— | -0.65—— | |
| Shares, weighted average (basic) | 0.1+22.4%— | 0.1r59−99.9%— | 51+26.4%— | 40+6.9%— | 38—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 0.1+36.4%— | 0.1r59−99.9%— | 51+26.4%— | 40+6.9%— | 38+31.9%— | 29+18.3%— | 24+35.6%— | 18r89−67.7%— | 55+45.2%— | 38—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 145+256%17.5% | 41r41−6.9%34.2% | 44+1.1%53.2% | 43−19.1%69.6% | 53+27.2%77.3% | 42+156%85.0% | 16−7.2%55.5% | 18+69.8%93.6% | 10+28.7%77.2% | 8.1—36.8% | |
| Short-term investments | 3.7−66.5%0.4% | 11r11−65.9%9.3% | 32+107%39.5% | 16+28.8%25.2% | 12+173%17.6% | 4.4−62.9%9.0% | 12—40.7% | 0−100%0.0% | 1.6−86.7%11.9% | 12—55.2% | |
| Receivables | 171+231%20.7% | 52r52—43.5% | — | — | — | — | — | 0.0−83.0%0.1% | 0.1+434%0.5% | 0.0—0.1% | |
| Inventory | 30+291%3.6% | 7.6r7.6+261%6.4% | 2.1—2.6% | — | 0.0−97.9%0.0% | 0.1−57.6%0.3% | 0.3−21.0%1.1% | 0.4−27.9%2.3% | 0.6+256%4.4% | 0.2—0.8% | |
| Other current assets | 18+384%2.1% | 3.6r3.5+312%3.1% | 0.9+41.5%1.1% | 0.6−19.1%1.0% | 0.8−45.4%1.1% | 1.4+216%2.9% | 0.4+5.7%1.5% | 0.4+15.0%2.2% | 0.4−1.3%2.7% | 0.4—1.7% | |
| Current assets | 367+220%44.4% | 115r115+44.2%96.4% | 79+33.4%96.8% | 60−10.4%96.0% | 66+38.0%96.4% | 48+64.2%97.7% | 29+57.2%99.6% | 19+40.7%99.1% | 13−39.2%98.6% | 22—99.7% | |
| Property, plant and equipment | 6.0+226%0.7% | 1.8r1.8−2.0%1.5% | 1.9+15.9%2.3% | 1.6+9.1%2.6% | 1.5+1223%2.1% | 0.1−8.7%0.2% | 0.1r0.1−24.1%0.4% | 0.2−13.6%0.9% | 0.2+167%1.4% | 0.1—0.3% | |
| Right-of-use (leased) assets | 3.0+513%0.4% | 0.5r0.5−23.0%0.4% | 0.6−17.4%0.8% | 0.8−13.8%1.2% | 0.9−11.3%1.3% | 1.0+21534%2.1% | 0.0—0.0% | — | — | — | |
| Goodwill | 30—3.6% | — | — | — | — | — | — | — | — | — | |
| Other intangible assets | 379+20457%45.9% | 1.8r1.8—1.6% | — | — | — | — | — | — | — | — | |
| Total assets | 826+595%100% | 119r119+44.8%100% | 82+32.3%100% | 62−10.0%100% | 69+39.8%100% | 49+67.3%100% | 29+56.6%100% | 19+39.9%100% | 13−38.6%100% | 22—100% | |
| Accounts payable | 7.9+358%1.0% | 1.7r1.7−59.8%1.4% | 4.3+94.3%5.2% | 2.2−0.3%3.5% | 2.2+95.9%3.2% | 1.1+10.1%2.3% | 1.0−60.4%3.5% | 2.6+43.2%13.8% | 1.8+9.9%13.4% | 1.6—7.5% | |
| Current liabilities | 174+415%21.1% | 34r34+197%28.5% | 11+80.6%13.9% | 6.3+18.1%10.2% | 5.3+28.4%7.8% | 4.2−28.6%8.4% | 5.8−25.0%19.8% | 7.8+24.0%41.3% | 6.3+53.0%46.5% | 4.1—18.7% | |
| Lease liabilities (non-current) | 2.3+546%0.3% | 0.3r0.3−32.5%0.3% | 0.5−22.6%0.6% | 0.7−16.8%1.1% | 0.8−13.1%1.2% | 0.9+34392%1.9% | 0.0—0.0% | 0—0.0% | — | — | |
| Total liabilities | 421+1131%50.9% | 34r34+187%28.8% | 12+70.8%14.5% | 7.0+13.5%11.2% | 6.1+20.9%8.9% | 5.1−12.8%10.3% | 5.8−58.0%19.8% | 14+122%73.8% | 6.3+53.0%46.5% | 4.1—18.7% | |
| Retained earnings | −177—−21.4% | −340r−340—−286% | −322—−392% | −275—−444% | −246—−356% | −217—−441% | −195—−663% | −179—−951% | −152—−1131% | −119—−544% | |
| Shareholders' equity | 405+379%49.1% | 85r85+20.7%71.2% | 70r70+27.4%85.5% | 55−12.3%88.8% | 63+42.0%91.1% | 44+87.0%89.7% | 24+379%80.2% | 4.9r4.9−31.4%26.2% | 7.2−59.6%53.5% | 18—81.3% | |
| Total liabilities and equity | 826+595%100% | 119r119+44.8%100% | 82+32.3%100% | 62−10.0%100% | 69+39.8%100% | 49+67.3%100% | 29+56.6%100% | 19+39.9%100% | 13−38.6%100% | 22—100% | |
| Shares outstanding | 79+23.1%— | 64+17.2%— | 55+28.3%— | 43+12.4%— | 38+13.5%— | 34+30.8%— | 26+17.9%— | 22r22−69.5%— | 71+76.6%— | 40—— | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 14+126%4.4% | 6.1r6.1+11.6%14.1% | 5.5+35.0%— | 4.1−19.3%6222% | 5.0+102%2641% | 2.5+2.5%1045% | 2.4+120%861% | 1.1−33.1%258% | 1.7+24.3%504% | 1.3—596% | |
| Cash from operating activities | 175—56.2% | −51r−51—−116% | −38—— | −24—−37238% | −21—−11080% | −22—−9183% | −15—−5314% | −24—−5514% | −29—−8680% | −22—−9935% | |
| Capital expenditure | −2.3—−0.7% | −0.1r−0.1—−0.3% | −0.3—— | −0.2—−335% | −1.4—−746% | −0.1—−47.1% | −0.0—−12.9% | −0.0—−11.4% | −0.2—−46.2% | −0.1—−26.2% | |
| Acquisitions, net of cash acquired | −309—−99.0% | — | — | — | — | — | — | — | — | — | |
| Cash from investing activities | −308−1553%−98.9% | 21r21—48.8% | −17—— | −3.7—−5671% | −9.1−223%−4784% | 7.4—3104% | −12−873%−4244% | 1.6−85.0%362% | 10−9.3%3145% | 11—5096% | |
| Shares issued | 7.8−58.8%2.5% | 19r19+45.8%43.4% | 13−27.1%— | 18−57.1%27167% | 41+125%21712% | 18+21.0%7705% | 15—5378% | 0−100%0.0% | 0.3—91.0% | 0—0.0% | |
| Cash from financing activities | 238+806%76.5% | 26r26−52.9%60.5% | 56+212%— | 18−57.1%27364% | 42+4.1%21870% | 40+55.4%16762% | 26−12.2%9110% | 29+43.2%6840% | 21+189%6232% | 7.1—3165% | |
| Exchange-rate effect on cash | — | −0.0r−0.0−171%−0.0% | 0.0—— | −0.0—−13.3% | −0.0−198%−6.8% | 0.0—5.5% | −0.0—−0.7% | −0.0−140%−1.8% | 0.0+7893%5.9% | 0.0—0.1% | |
| Change in cash | 105—33.7% | −3.1r−3.1−784%−7.1% | 0.4—— | −10−189%−15559% | 11−55.2%5999% | 26—10689% | −1.3−118%−448% | 7.2+213%1685% | 2.3—703% | −3.8—−1675% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 412+92.5%100% | 55−47.7%100% | 102+157%100% | 127+226%100% | 129*+312%100% | 104+810%100% | 40+4829%100% | 39—100% | 31r31*—100% | 11—100% | 0.8—100% | — | — | |
| Cost of revenue | — | — | — | 12+677%9.4% | 11*+895%8.7% | 7.6+1092%7.3% | 1.9+265%4.7% | 1.5r1.6+88.8%4.0% | 1.1r1.2*—3.6% | 0.6r0.7—5.5% | 0.5—63.2% | 0.8—— | — | |
| Gross profit | 320+61.0%77.5% | 30−67.8%55.0% | 77+104%75.7% | 105+180%82.5% | 107r107*+257%83.4% | 93r93+764%89.3% | 38r38+12683%95.3% | 37r37—95.9% | 30r30*—96.2% | 11—94.0% | 0.3—36.8% | −0.8—— | — | |
| Research and development | 30+137%7.2% | 7.0+38.0%12.9% | 6.7+174%6.6% | 7.2+126%5.7% | 8.6r8.6*+398%6.7% | 5.1r5.1+601%4.9% | 2.4r2.4+275%6.1% | 3.2r3.2+281%8.2% | 1.7r1.7*−24.6%5.5% | 0.7—6.3% | 0.7—80.8% | 0.8—— | 2.3*—— | |
| Selling, general and administrative | — | — | — | — | — | — | — | — | — | — | — | 15—— | 13*—— | |
| Selling and marketing | 53+73.8%12.8% | 12+4.4%21.4% | 12+95.0%12.2% | 13+180%9.8% | 16r16*+93.7%12.4% | 11r11+65.7%10.7% | 6.4r6.4−13.6%16.1% | 4.5r4.5−29.4%11.4% | 8.3r8.3*+1.3%26.5% | 6.7—58.9% | 7.4—916% | 6.3—— | 8.2*—— | |
| General and administrative | 78+51.3%19.0% | 18−29.7%32.8% | 15+58.7%14.8% | 22+124%17.0% | 24r24*+232%18.3% | 25r25+287%24.4% | 9.5r9.5+25.7%23.9% | 9.7r9.7+11.3%24.8% | 7.1r7.1*+36.2%22.8% | 6.6—57.4% | 7.6—938% | 8.7—— | 5.2*—— | |
| Operating expenses | 160+69.8%38.9% | 37−12.2%67.2% | 34+86.7%33.6% | 41+139%32.5% | 48r48*+182%37.5% | 42r42+197%40.0% | 18r18+17.5%46.1% | 17r17+9.3%44.4% | 17r17*+9.1%54.8% | 14—123% | 16—1935% | 16—— | 16*—— | |
| Operating income | 159+53.0%38.6% | −6.6−113%−12.1% | 43+120%42.1% | 64+216%50.0% | 59r59*+357%46.0% | 51r51—49.2% | 20r20—49.2% | 20r20—51.5% | 13r13*—41.4% | −3.3—−28.7% | −15—−1898% | −17—— | −16*—— | |
| Interest and finance income | — | — | — | — | 0.9*+74.3%0.7% | 1.6+182%1.5% | 0.8+26.1%2.1% | 0.6−33.9%1.5% | 0.5r0.5*−44.5%1.6% | 0.6—4.8% | 0.7—81.5% | 0.9—— | 0.9*—— | |
| Interest expense and finance costs | — | — | — | — | 1.8*+18824%1.4% | 0.9+9376%0.9% | 0.0+1.8%0.0% | 0.0+1.7%0.0% | 0.0r0.0*+46.5%0.0% | 0.0—0.1% | 0.0—0.8% | 0.0—— | 0.0*—— | |
| Other non-operating income (expense) | −25−901%−6.0% | −9.8−899%−18.0% | −4.2−618%−4.1% | −8.0−1644%−6.3% | −2.7r−2.7*−608%−2.1% | 1.2r1.2+141%1.2% | 0.8r0.8−29.9%2.0% | 0.5r0.5−38.5%1.3% | 0.5r0.5*−42.3%1.7% | 0.5—4.5% | 1.1—143% | 0.8—— | 0.9*—— | |
| Income before tax | 134+25.5%32.6% | −16−131%−30.2% | 39+90.3%38.0% | 56+170%43.7% | 56r56*+319%43.9% | 53r53—50.4% | 20r20—51.2% | 21r21—52.8% | 13r13*—43.1% | −2.8—−24.2% | −14—−1756% | −16—— | −15*—— | |
| Income tax | 70—17.1% | −1.7—−3.2% | 13+2342%12.5% | 17—13.4% | 42r42*—33.0% | −56r−56—−53.7% | 0.5r0.5—1.3% | 0—0.0% | −0.0r0*—−0.0% | 0*—0.0% | 0*—0.0% | −1.4—— | — | |
| Income from continuing operations | — | — | — | — | 0*—0.0% | — | 2.0—5.1% | — | — | — | — | — | — | |
| Net income attributable to shareholders | 64−60.7%15.5% | −15−114%−27.0% | 26+31.1%25.5% | 39+87.0%30.3% | 14r14*+4.1%10.9% | 109r109—104% | 20r20—49.9% | 21r21—52.8% | 13r13*—43.1% | −2.8—−24.2% | −14—−1756% | −14—— | −15*—— | |
| Earnings per share, basic | — | -0.19−113%— | 0.33+13.8%— | 0.48+50.0%— | — | 1.42—— | 0.29—— | 0.32—— | — | -0.05—— | -0.25—— | -0.25—— | — | |
| Earnings per share, diluted | — | -0.19−115%— | 0.29+3.6%— | 0.43+43.3%— | — | 1.26—— | 0.28—— | 0.30—— | — | -0.05—— | -0.25—— | -0.25—— | — | |
| Shares, weighted average (basic) | 78+3.3%— | 78+3.3%— | 78+15.5%— | 80+21.9%— | — | 76r76+29.1%— | 68r68+17.9%— | 65r65+13.5%— | — | 59—— | 58—— | 58—— | — | |
| Shares, weighted average (diluted) | 78−9.0%— | 78−9.0%— | 92+28.6%— | 93+34.8%— | — | 86r86+46.6%— | 72r72+24.8%— | 69r69+19.9%— | — | 59—— | 58—— | 58—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 355—38.7% | 355+632%38.7% | 257+61.1%28.4% | 178+169%21.8% | 145+256%17.5% | 48r48+37.4%6.5% | 159r159+458%63.1% | 66r66+88.4%44.3% | 41r41−6.9%34.2% | 35—45.5% | 29—49.4% | 35—51.7% | 44—53.2% | |
| Short-term investments | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 3.7−66.5%0.4% | 7.2−32.8%1.0% | 31+84.0%12.4% | 11−52.0%7.5% | 11r11−65.9%9.3% | 11—13.8% | 17—29.6% | 23—34.4% | 32—39.5% | |
| Receivables | 77—8.4% | 77−51.6%8.4% | 161+276%17.8% | 155+183%19.0% | 171+231%20.7% | 159+812%21.1% | 43+20697%17.0% | 55—36.5% | 52r52—43.5% | 17—22.4% | 0.2—0.4% | — | — | |
| Inventory | 43—4.7% | 43+49.2%4.7% | 39+300%4.3% | 31+310%3.8% | 30+291%3.6% | 29+335%3.9% | 9.6+140%3.8% | 7.5+223%5.0% | 7.6r7.6+261%6.4% | 6.6—8.6% | 4.0—6.9% | 2.3—3.4% | 2.1—2.6% | |
| Other current assets | 28—3.1% | 28+71.4%3.1% | 24+413%2.7% | 19+280%2.4% | 18+384%2.1% | 16+460%2.2% | 4.7+49.0%1.9% | 5.1+137%3.4% | 3.6r3.5+312%3.1% | 2.9—3.8% | 3.1—5.4% | 2.2—3.2% | 0.9—1.1% | |
| Current assets | 503—54.8% | 503+93.8%54.8% | 481+93.7%53.2% | 383+164%47.0% | 367+220%44.4% | 260+255%34.6% | 248+366%98.2% | 145+128%96.8% | 115r115+44.2%96.4% | 73—94.3% | 53—92.1% | 63—93.2% | 79—96.8% | |
| Property, plant and equipment | 8.6—0.9% | 8.6+97.0%0.9% | 7.9+378%0.9% | 6.2+257%0.8% | 6.0+226%0.7% | 4.3+129%0.6% | 1.6−14.3%0.6% | 1.7−9.3%1.2% | 1.8r1.8−2.0%1.5% | 1.9—2.4% | 1.9—3.3% | 1.9—2.8% | 1.9—2.3% | |
| Right-of-use (leased) assets | — | — | — | — | 3.0+513%0.4% | 3.2+498%0.4% | 0.4−27.2%0.2% | 0.5−25.0%0.3% | 0.5r0.5−23.0%0.4% | 0.5—0.7% | 0.6—1.0% | 0.6—0.9% | 0.6—0.8% | |
| Goodwill | 30—3.3% | 30+71.3%3.3% | 30—3.3% | 30—3.7% | 30—3.6% | 18—2.3% | — | — | — | — | — | — | — | |
| Other intangible assets | 348—37.9% | 348−10.7%37.9% | 358+20499%39.7% | 369+20476%45.2% | 379+20457%45.9% | 390+20469%51.9% | 1.7—0.7% | 1.8—1.2% | 1.8r1.8—1.6% | 1.9—2.4% | — | — | — | |
| Total assets | 918—100% | 918+22.2%100% | 904+258%100% | 816+445%100% | 826+595%100% | 751+868%100% | 253+338%100% | 150+120%100% | 119r119+44.8%100% | 78—100% | 58—100% | 68—100% | 82—100% | |
| Accounts payable | 10—1.1% | 10−49.5%1.1% | 10+76.1%1.1% | 13+564%1.6% | 7.9+358%1.0% | 20+1422%2.7% | 5.8+73.9%2.3% | 1.9−31.6%1.3% | 1.7r1.7−59.8%1.4% | 1.3—1.7% | 3.3—5.8% | 2.8—4.2% | 4.3—5.2% | |
| Current liabilities | 207—22.6% | 207+55.1%22.6% | 187+491%20.7% | 129+274%15.8% | 174+415%21.1% | 134+623%17.8% | 32+185%12.6% | 34+261%23.0% | 34r34+197%28.5% | 18—23.8% | 11—19.2% | 9.5—14.0% | 11—13.9% | |
| Lease liabilities (non-current) | — | — | — | — | 2.3+546%0.3% | 2.4+514%0.3% | 0.3−40.7%0.1% | 0.3−36.2%0.2% | 0.3r0.3−32.5%0.3% | 0.4—0.5% | 0.4—0.8% | 0.5—0.7% | 0.5—0.6% | |
| Total liabilities | 456—49.7% | 456+21.1%49.7% | 443+1286%49.0% | 379+991%46.4% | 421+1131%50.9% | 377+1896%50.2% | 32+177%12.7% | 35+247%23.2% | 34r34+187%28.8% | 19—24.3% | 12—20.0% | 10—14.7% | 12—14.5% | |
| Retained earnings | −127—−13.8% | −127—−13.8% | −112—−12.4% | −138—−16.9% | −177—−21.4% | −191—−25.4% | −299—−118% | −319—−213% | −340r−340—−286% | −353—−455% | −350—−607% | −336—−494% | −322—−392% | |
| Shareholders' equity | 462—50.3% | 462+23.4%50.3% | 461+109%51.0% | 437+280%53.6% | 405+379%49.1% | 374r374+537%49.8% | 221r221+378%87.3% | 115r115+98.0%76.8% | 85r85+20.7%71.2% | 59—75.7% | 46—80.0% | 58—85.3% | 70r70—85.5% | |
| Total liabilities and equity | 918—100% | 918+22.2%100% | 904+258%100% | 816+445%100% | 826+595%100% | 751+868%100% | 253+338%100% | 150+120%100% | 119r119+44.8%100% | 78—100% | 58—100% | 68—100% | 82—100% | |
| Shares outstanding | 79—— | 79+1.4%— | 78+4.1%— | 78+15.8%— | 79+23.1%— | 78+35.3%— | 75+35.0%— | 68+23.2%— | 64+17.2%— | 58—— | 55—— | 55—— | 55—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | 11*+178%19.3% | 11*+6366%10.3% | 11+6409%8.3% | — | 3.8*—3.6% | 0.2*—0.4% | 0.2—0.4% | — | — | — | — | — | |
| Share-based compensation | 16+41.6%3.9% | 3.9−3.2%7.2% | 4.1+52.6%4.0% | 4.6+30.9%3.6% | 3.6r3.6*+201%2.8% | 4.1r4.1+231%3.9% | 2.7r2.7+112%6.7% | 3.5r3.5+43.2%9.0% | 1.2r1.2*−2.0%3.8% | 1.2—10.7% | 1.3—157% | 2.4—— | 1.2*—— | |
| Cash from operating activities | 313+317%75.8% | 90*+191%165% | 86*+188%84.6% | 42+115%33.3% | 94r94*—73.4% | 31r31*—29.6% | 30r30*—75.5% | 20r20—50.5% | −5.6r−5.6*—−18.0% | −14*—−119% | −14*—−1742% | −17—— | −11*—— | |
| Capital expenditure | −4.9—−1.2% | −1.9*—−3.5% | −0.6*—−0.6% | −0.7—−0.6% | −1.7r−1.7*—−1.3% | −0.5r−0.5*—−0.5% | −0.0r−0.0*—−0.1% | −0.0r−0.0—−0.0% | −0.0r−0.0*—−0.0% | −0.0*—−0.1% | −0.0*—−4.3% | −0.1—— | −0.3*—— | |
| Cash from investing activities | 3.8—0.9% | −1.9*—−3.5% | −0.6*—−0.6% | 3.0—2.3% | 3.3r3.3*—2.6% | −291r−291*−4708%−279% | −20r−20*−422%−50.9% | −0.2r−0.2−102%−0.5% | −0.3r−0.3*−151%−1.0% | 6.3*—55.2% | 6.3*—778% | 8.9—— | 0.6*—— | |
| Shares issued | 11−9.0%2.7% | 10*—18.6% | 0*—0.0% | 0−100%0.0% | 1.0r1.0*−81.4%0.8% | 0r0*−100%0.0% | 0r0*—0.0% | 6.8r6.8—17.3% | 5.5r5.5*+1169%17.6% | 12*—108% | — | — | 0.4*—— | |
| Shares bought back | — | 0*—0.0% | −6.4*—−6.3% | −11—−8.7% | — | 0*—0.0% | 0*—0.0% | 0—0.0% | — | — | — | — | — | |
| Cash from financing activities | −9.9−104%−2.4% | 11*−92.9%19.6% | −7.1*−108%−6.9% | −12−299%−9.5% | −1.4r−1.4*−113%−1.1% | 151r151*+970%144% | 83r83*+7778%209% | 6.1r6.1—15.6% | 11r11*+2313%36.2% | 14*—123% | 1.1*—131% | −0.1—— | 0.5*—— | |
| Exchange-rate effect on cash | — | 0*—0.0% | 0*−100%0.0% | 0—0.0% | — | 0r0.0*−100%0.0% | 0.0r0.0*—0.0% | 0r0.0—0.0% | −0.0r−0.0*−163%−0.0% | 0.0*—0.0% | −0.0*—−0.0% | −0.0—— | 0.0*—— | |
| Change in cash | 307+2076%74.3% | 98*—181% | 79*−15.5%77.1% | 33+29.7%26.1% | 96r96*+1696%74.9% | −110r−110*−1730%−105% | 93r93*—234% | 26r26—65.6% | 5.4r5.4*—17.2% | 6.7*—58.9% | −6.7*—−833% | −8.5—— | −9.7*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What CorMedix Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product Sales, Net(total)$304 M98%+600%
- DefenCath$259 M83%+495%
- Melinta Portfolio$46 M15%—
- Contract revenue$7 M2.4%—
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at CorMedix Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Joseph Todisco | $6.1 M | $8.9 M | $3.8 M | $276 |
| 2024Joseph Todisco | $2.4 M | $5.4 M | $1.1 M | $192 |
| 2023Joseph Todisco | $2.5 M | $1.9 M | $1.2 M | $89 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at CorMedix Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Auditor changed 2 · Acquisition or sale completed 1 · Directors and officers 2 · Material agreement 4 · New debt 1 · Unregistered share sale 4 · Shareholder vote 2 · Results announced 12
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersResults announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Acquisition or sale completedDirectors and officersMaterial agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share saleResults announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
2 acquisitions, $477 M paid where reported · 1 private funding rounds before listing
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| Acquisition of Melinta | 2025 | — | $454 M | — | Annual report |
| Toprol XL | 2025 | — | $23 M | — | Annual report |
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2009 | $3 M | No. 1 | $2 to $10 million | 19 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by CorMedix Inc.#
$650 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.
- Health Issues4 reports
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $800 K | $800 K | 3 |
| 2025 | $650 K | $650 K | 4 |
| 2024 | $870 K | $870 K | 10 |
| 2023 | $670 K | $590 K | 12 |
| 2021 | $0 | — | 2 |
| 2020 | $0 | — | 4 |
| 2019 | $0 | — | 4 |
| 2018 | $30 K | — | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “CorMedix Inc.”, “Cormedix” and “CorMedix, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
FDA drug approvals: CorMedix Inc.#
1 approved applications held, 1 of them new molecular entities; 1 approvals and 0 new uses in 2023.
| Approved | Drug | Kind |
|---|---|---|
| 2023-11-15 | Defencathnew moleculeHeparin Sodium, Taurolidine · NDA214520 | New drug (NDA) |
Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (CORMEDIX), so they follow acquisitions
Discuss CorMedix Inc.#
3 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 12 November 2026automatic update · Nov 12, 2026
CorMedix Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: revenue of $55 million (down 48% from a year earlier) and a net loss of $15 million.
- Results announced on 2 November 2026automatic update · Nov 2, 2026
CorMedix Inc. announced results on 2 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: revenue of $55 million (down 48% from a year earlier) and a net loss of $15 million.
- Mutual funds: 104 funds hold $123 millionautomatic update · Jul 31, 2026
104 mutual funds in 1 country hold shares of CorMedix Inc. worth $123 million, about 19.6% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 52 funds added shares and 41 sold; on balance they bought $3 million. Share splits are not counted as trading.
How CorMedix Inc. compares in Biotechnology
- Market cap$652 M · higher than 62% of 726
- Revenue$312 M · higher than 82% of 647
- Net margin15.5% · higher than 82% of 408
- Revenue growth617.1% · higher than 95% of 438
- P/E ratio10.2× · lower than 73% of 100
- Price / sales1.6× · lower than 89% of 339
- Price / book1.6× · lower than 65% of 534
- FCF yield26.5% · highest of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| CorMedix Inc.🇺🇸 | $652 M | 10.2× | 15.5% | +617.1% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of February 28, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at CorMedix Inc.? Verify and update this profile — free
Show CorMedix Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.